Potential mechanisms of resistance to cytarabine in AML patients.

[1]  J. Mackey,et al.  Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. , 2001, Blood.

[2]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[3]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[4]  J. Mackey,et al.  Nucleoside transporters: molecular biology and implications for therapeutic development. , 1999, Molecular medicine today.

[5]  J. Zalcberg,et al.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line , 1999, British Journal of Cancer.

[6]  M. Baccarani,et al.  P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications , 1999, British journal of haematology.

[7]  S. Seeber,et al.  Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia , 1998, British journal of haematology.

[8]  R. Herrmann,et al.  Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias , 1997 .

[9]  C. Cass,et al.  Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells , 1997, Neuropharmacology.

[10]  W. Hiddemann,et al.  Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy , 1997, Blood.

[11]  B. Goz,et al.  A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine. , 1997, Mutation research.

[12]  A. Paterson,et al.  Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. , 1997, Blood.

[13]  S. Seeber,et al.  Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. , 1996, Leukemia.

[14]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.

[15]  M. Tribalto,et al.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. , 1996, Blood.

[16]  J. Laliberté,et al.  Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. , 1994, Cancer research.

[17]  G. Juliusson,et al.  Phosphorylation of 2‐chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients , 1994, British journal of haematology.

[18]  L. Zwelling,et al.  Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia , 1994 .

[19]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[20]  T. Kipps,et al.  Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. , 1993, Blood.

[21]  R. Pieters,et al.  Hypoxanthine‐guanine phosphoribosyl‐transferase in childhood leukemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosis , 1992, International journal of cancer.

[22]  R. Pieters,et al.  The role of 5'nucleotidase in therapy-resistance of childhood leukemia. , 1988, Medical hypotheses.

[23]  D. Richel,et al.  Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. , 1987, Seminars in oncology.

[24]  E. Estey,et al.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. , 1987, Seminars in oncology.

[25]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[26]  L. R. Finch,et al.  Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. , 1985, The Journal of clinical investigation.

[27]  D. Kufe,et al.  Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. , 1982, Biochemical pharmacology.

[28]  D. Kufe,et al.  Correlation of cytotoxicity with incorporation of ara-C into DNA. , 1980, The Journal of biological chemistry.

[29]  R. Wohlhueter,et al.  Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. , 1978, Cancer research.

[30]  C. N. Coleman,et al.  Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. , 1975, Blood.

[31]  M. Tattersall,et al.  Mechanisms of Resistance of Human Acute Leukaemia Cells to Cytosine Arabinoside , 1974, British journal of haematology.

[32]  C. D. Steuart,et al.  Cytidine deaminase and the development of resistance to arabinosyl cytosine. , 1971, Nature: New biology.

[33]  A. Paterson,et al.  Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). , 1998, Leukemia & lymphoma.

[34]  J. Mackey,et al.  Nucleoside transport and its significance for anticancer drug resistance. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.

[36]  D. Hipfner,et al.  Characterization of the Mr 190,000 Multidrug Resistance Protein (MRP) in Drug-selected and Transfected Human Tumor Cells , 1995 .

[37]  A. Veerman,et al.  Prognostic value of 5'nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. , 1985, Leukemia research.